Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Sickle cell disease reversed in mice

17 October 2011

By Mehmet Fidanboylu

Appeared in BioNews 629

The blood condition sickle cell disease may be reversed by turning off a single gene, according to scientists in the USA. By inactivating a single gene in red blood cells the researchers were able to alleviate symptoms of the disease in mice, offering the hope of a potential new treatment for humans.

Before birth, babies produce a special form of haemoglobin - the protein in red blood cells that fixes oxygen, enabling its transport around the body - which allows them to obtain oxygen from the mother via the placenta. Shortly after birth a switch occurs and the baby will start to produce adult rather than fetal haemoglobin. It is at this point that sickle cell disease can come to light, leading to symptoms including anaemia, pain and organ damage. The condition is potentially lethal.

Sickle cell disease is caused by a genetic mutation in adult haemoglobin that affects approximately 1 in 5000 people, and is more common in people of African origin. In sickle cell disease the mutated haemoglobin causes red blood cells to form rigid sickle shapes that mean they do not flow through small blood vessels as well as they should.

A team of researchers at Harvard Medical School and Howard Hughes Medical Institute in Boston, USA, previously identified the gene BCL11A as being important for the switch from producing fetal to adult haemoglobin. BCL11A is one of the molecular switches that help to stop production of fetal haemoglobin not long after birth, allowing production of the adult form to take over.

For their latest study, published in the journal Science, the researchers found that inactivating BCL11A in developing red blood cells caused adult mice to start producing fetal haemoglobin. This finding was replicated in two different mouse models of human sickle cell disease, and in both instances the mice started producing red blood cells with no 'sickling'. Up to 85 percent of red blood cells carried fetal haemoglobin, reversing the clinical symptoms of the disease.

'We knew from previous clinical studies that the body needs to produce cells containing only 15 to 20 percent fetal haemoglobin to reverse disease', said Professor Stuart Orkin, the leader of the research team. 'With these results, we know now we have a target that, if we can develop ways to inactivate or silence it clinically, could be very beneficial to people with sickle cell'.

Currently, the most effective treatment option for sickle cell disease is a bone marrow transplant. However, this requires a compatible donor and can lead to complications associated with transplantation. Another option is the drug hydroxyurea, however scientists do not currently understand how or why it works, and it is not effective in all patients.

By reversing the symptoms of sickle cell disease in mice, this study has identified the potential for future drugs targeting BCL11A. However, Professor Alex Felice, a haematologist and molecular genetics expert at the University of Malta, has warned that success in animal models does not guarantee success in humans. He told ScienceNOW that in humans 'BCL11A is expressed in other blood cell types' meaning that silencing it could be problematic.

SOURCES & REFERENCES
Science | 13 October 2011
 
Harvard Gazette, HarvardScience | 13 October 2011
 
Howard Hughes Medical Institute press release | 13 October 2011
 
Reuters | 13 October 2011
 
New Scientist | 13 October 2011
 
Science Magazine | 13 October 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

14 November 2016 - by Sarah Gregory 
Researchers have had further success using the CRISPR/Cas9 genome-editing technique to repair the mutation that causes sickle-cell anaemia...
17 October 2016 - by Sarah Gregory 
Researchers have used the CRISPR/Cas9 genome-editing technique to correct the mutation that causes sickle-cell anaemia...
12 September 2016 - by Dr Nicoletta Charolidi 
A genetically engineered virus that triggers the production of an alternative form of haemoglobin has reversed the symptoms of sickle cell disease in mice...

27 September 2010 - by Seil Collins 
The US National Collegiate Athletic Association (NCAA) has introduced new legislation requiring all incoming students at the highest level of intercollegiate athletics to be tested for sickle cell trait. The testing, which will affect approximately 170,000 incoming student-athletes, is being watched closely as a case study of modern large-scale genetic screening...
14 December 2009 - by Ailsa Stevens 
Adults with the inherited blood disorder 'sickle cell anaemia' may be treated using blood stem cells transplanted from a healthy tissue-matched donor, scientists based at the US National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Maryland, have shown. The treatment successfully boosted levels of normal red blood cells in nine out of 10 of the adults who have so far been given the experimental therapy, according to a study published in the New England J...
10 August 2009 - by Nisha Satkunarajah 
The deaths of student-athletes due to complications of sickle-cell trait has led the US's National Collegiate Athletic Association to recommend that all student-athletes should be tested for the condition. Dale Lloyd II died in 2006 after suffering 'exertional sickling' caused by overexertion during an early morning practice and...
27 July 2009 - by Dr Will Fletcher 
Chinese scientists have created 27 healthy mice from reprogrammed cells known as induced pluripotent stem (iPS) cells. The iPS cells were reprogrammed from adult mouse skin cells by modifying four key genes using retroviruses, turning them into an embryo-like state. iPS cells are a hot research topic at present as they offer the prospect of a limitless supply of an individual's own stem cells if the technique is replicated in humans, potentially avoiding the pitfal...
10 December 2007 - by Katy Sinclair 
By Katy Sinclair: Researchers, reporting in Science, have announced the successful treatment of a mouse with sickle-cell anaemia using stem cell lines created from adult mouse cells. Rudolf Jaenisch, of the Whitehead Institute for Biomedical Research in Cambridge Massachusetts, and Tim Townes, of the University of Alabama at Birmingham, worked...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation